---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-139440"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:59:49.523201+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28

## Summary
- Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.
- Humphrey brings 30+ years clinical oncology experience from Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.
- Provost transitions from CMO to CSO to lead business development and pipeline acceleration; holds medicine degree from Sorbonne University.
- CEO Markison says moves will 'enable our team to accelerate innovation' in radiopharmaceutical diagnostics and therapeutics.

## SEC filing metadata
- accession: 0001193125-24-139440
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/0001193125-24-139440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/d824247d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-139440
- JSON: https://secwatch.observer/filing/0001193125-24-139440.json
- Plain text: https://secwatch.observer/filing/0001193125-24-139440.txt

## Key facts
- Executive change
  Jean-Claude Provost was appointed as Chief Science Officer at Lantheus Holdings, Inc..
  - Action: appointed
  - Role: Chief Science Officer
  source text: On May 15, 2024, Lantheus Holdings, Inc. (the “Company”) announced that, upon the effectiveness of his appointment as Chief Science Officer of the Company on May 28, 2024, Jean-Claude Provost MD will no longer serve as the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/0001193125-24-139440-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.